Paxlovid Boceprevir Intermediate CAS 565456-77-1 Assay ≥99.0%

Short Description:

Name: (1R,2S,5S)-6,6-Dimethyl-3-azabicyclo[3.1.0]hexane-2-Carboxylic Acid Methyl Ester Hydrochloride

CAS: 565456-77-1

Appearance: White to Off-White Powder 

Assay: ≥99.0%

Intermediate of PF-07321332 Paxlovid (CAS 2628280-40-8) and Boceprevir (CAS 394730-60-0)

High Quality, Commercial Production

Inquiry: alvin@ruifuchem.com


Product Detail

Related Products

Product Tags

Description:

Chemical Properties:

Chemical Name (1R,2S,5S)-6,6-Dimethyl-3-azabicyclo[3.1.0]hexane-2-Carboxylic Acid Methyl Ester Hydrochloride 
Synonyms Methyl (1R,2S,5S)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxylate Hydrochloride
CAS Number 565456-77-1
CAT Number RF-PI318
Stock Status In Stock, Production Scale Up to Tons
Molecular Formula C9H15NO2.ClH
Molecular Weight 205.683
Brand Ruifu Chemical

Specifications:

Item Specifications
Appearance White to Off-White Powder
Identification A IR: Similar to Reference Substance
Identification B Retention Time: Similar to Reference Substance
Enantiomer ≤0.15%
Related Impurity (by HPLC)
Unknown Impurity ≤0.20%
Total Impurities ≤1.0%
Water ≤0.50%
Residue on Ignition ≤0.10%
Heavy Metals ≤20ppm
Assay ≥99.0%
Test Standard Enterprise Standard
Usage Intermediate of PF-07321332 Paxlovid (CAS 2628280-40-8) and Boceprevir (CAS 394730-60-0)

Package & Storage:

Package: Bottle, Aluminum foil bag, Cardboard drum, 25kg/Drum, or according to customer's requirement.

Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation.

Advantages:

1

FAQ:

Application:

(1R,2S,5S)-6,6-Dimethyl-3-azabicyclo[3.1.0]hexane-2-Carboxylic Acid Methyl Ester Hydrochloride (CAS 565456-77-1) is an azabicyclohexane derivative used in the preparation of hepatitis C virus (HCV) NS3 serine protease inhibitor.  It's the intermediate of PF-07321332 Paxlovid (CAS 2628280-40-8) and Boceprevir (CAS 394730-60-0). PF-07321332 is a potent and orally active SARS-CoV 3C-like protease (3CLPRO) inhibitor . PF-07321332 targets to the SARS-CoV-2 virus and can be used for COVID-19 reseacrch. Boceprevir (INN, trade name Victrelis) is a protease inhibitor used as a treatment for hepatitis C genotype 1. It binds to HCV nonstructural 3 NS3 (HCV) active site. It was being developed by Schering-Plough, but is now being developed by Merck since Schering was acquired in 2009. It was approved by the FDA on May 13, 2011.

  • Write your message here and send it to us